Bär & Karrer Advises AC Immune on an Underwritten Offering of 14.3 Million of its Common Shares at a Price of USD 3.50 per Share

AC Immune SA, (Nasdaq: ACIU) a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases , completed an underwritten offering of 14.3 million of its common shares at a price of USD 3.50 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other offering expenses, is approximately USD 50.1 million.

Bär & Karrer acted as Swiss counsel to AC Immune. The team was led by Rolf Watter (Public Companies) and Shu Zhang (Capital Markets) and included Susanne Schreiber and Ariane Menzer (both Tax).